Key result
Higher urinary uromodulin linked to ~5% greater MI risk, mediated by blood pressure.
Why the study?
The causal links between urinary uromodulin and cardiovascular disease remained unclarified.
Does genetically predicted higher urinary uromodulin increase the risk of myocardial infarction in the general population?
Observational
Does genetically predicted higher urinary uromodulin increase the risk of myocardial infarction in the general population?
Higher urinary uromodulin levels increase blood pressure, which mediates a consequent effect on myocardial infarction risk.
Genetically predicted uromodulin may raise MI risk via BP; leaves open whether targeting it improves outcomes.
BACKGROUND: The causal links between urinary uromodulin (uUMOD) and cardiovascular disease (CVD) are still not clarified. METHODS: We first assessed the relationship between uUMOD and CVD using bidirectional 2-sample Mendelian randomization. Then, multivariable Mendelian randomization and product of the coefficients methods were used to investigate the role of blood pressure in mediating the effect of uUMOD on CVD. Our study did not support the causal effects of uUMOD on other CVD outcomes, including coronary artery disease, atrial fibrillation, heart failure, and ischemic stroke. In multivariable Mendelian Randomization, the direct effects of uUMOD on MI were attenuated to null after introducing systolic blood pressure or diastolic blood pressure. Mediation analysis showed that the indirect effect of uUMOD on MI mediated by systolic blood pressure or diastolic blood pressure was 1.05 ([95% CI, 1.04-1.06]; mediation proportion=69%) and 1.07 ([95% CI, 1.05-1.08]; mediation proportion=87%), respectively. Similar results were found in sensitivity analysis based on different sets of genetic instruments. CONCLUSIONS: Our findings provide evidence for the effect of higher uUMOD on increasing blood pressure, which mediates a consequent effect on MI risk in the general population. Further studies are necessary to verify the associations between uUMOD and other CVD outcomes.
No takes yet. Share an insight, caveat, or question.
Jian et al. (2022) conducted an observational in Myocardial Infarction. Urinary uromodulin (uUMOD) levels was evaluated on Myocardial infarction (indirect effect mediated by systolic blood pressure) (Indirect effect 1.05, 95% CI 1.04-1.06). Higher urinary uromodulin levels increased the risk of myocardial infarction, an effect largely mediated by systolic (indirect effect 1.05; 95% CI 1.04-1.06) and diastolic blood pressure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: